keyword
MENU ▼
Read by QxMD icon Read
search

Brivaracetam

keyword
https://www.readbyqxmd.com/read/28427029/treatment-of-refractory-and-super-refractory-status-epilepticus-with-brivaracetam-a-cohort-study-from-two-german-university-hospitals
#1
Adam Strzelczyk, Isabel Steinig, Laurent M Willems, Philipp S Reif, Christian Senft, Martin Voss, Bernadette Gaida, Felix von Podewils, Felix Rosenow
PURPOSE: We aimed to ascertain the possible use of brivaracetam (BRV) as an option for treatment of status epilepticus (SE). METHODS: A review of medical records was carried out to detect BRV administration in SE patients treated in Frankfurt and Greifswald during the period February 2016 to January 2017. The primary outcome question concerned SE resolution after BRV initiation. RESULTS: During that period, BRV was started with eleven adult patients with SE...
April 17, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/28394442/brivaracetam-an-adjunctive-treatment-for-partial-onset-seizures
#2
REVIEW
John A Kappes, William J Hayes, Joe D Strain, Debra K Farver
Brivaracetam is an analogue of levetiracetam that is Food and Drug Administration-approved for adjunctive treatment of partial-onset seizures in patients 16 years and older. In placebo-controlled trials adjunct brivaracetam demonstrated efficacy in reducing the frequency of seizures. The most commonly reported adverse effects are somnolence, dizziness, and fatigue. Clinical trials have evaluated brivaracetam for safety and efficacy in adjunctive treatment of partial-onset seizures in patients 16 years and older for up to 16 weeks...
April 10, 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28378057/tolerability-of-new-antiepileptic-drugs-a-network-meta-analysis
#3
REVIEW
Gaetano Zaccara, Fabio Giovannelli, Filippo Sean Giorgi, Valentina Franco, Sara Gasparini, Umberto Benedetto
OBJECTIVE: The objective of this study was to perform a comparative assessment of tolerability of all licensed new antiepileptic drugs (AEDs) through a network meta-analysis (NMA) including all placebo-controlled double-blind clinical trials (RCTs) in all conditions in which these drugs have been tested. METHODS: NMA with a frequentist approach was used to compare proportions of patients withdrawing because of adverse events (AEs). Analyses were conducted for all therapeutic doses pooled and specifically for high therapeutic doses...
April 4, 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28370224/do-antiepileptic-drugs-increase-the-risk-of-infectious-diseases-a-meta-analysis-of-placebo-controlled-studies
#4
Gaetano Zaccara, Fabio Giovannelli, Filippo Sean Giorgi, Valentina Franco, Sara Gasparini, Francesco Mandò Tacconi
AIMS: Experimental studies show that some antiepileptic drugs (AEDs) may modify natural immune defenses, thus influencing the risk of developing infectious diseases. The aim of this meta-analysis was to explore whether AEDs as a class of drugs or singularly may increase risk of infectious diseases. METHODS: A meta-analysis of all randomized, double-blind, placebo-controlled trials (RCTs) investigating any AED in any condition was performed. All terms which could be coded in the System Organ Classes (SOCs) of "infections and infestations" using the Medical Dictionary for Regulatory Activities (MedDRA) were recorded...
March 31, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28364655/real-life-experience-with-brivaracetam-in-101-patients-with-difficult-to-treat-epilepsy-a-monocenter-survey
#5
Bernhard J Steinhoff, Matthias Bacher, Iancu Bucurenciu, Barbara Hillenbrand, Tassanai Intravooth, Reinhold Kornmeier, Christoph Kurth, Jakob Stockinger, Anke M Staack
PURPOSE: To assess the efficiency of brivaracetam under real-world conditions in a tertiary referral epilepsy center. METHODS: We consecutively collected patients treated at our center with brivaracetam (BRV). After a minimum observation period of six months we retrospectively analyzed the efficiency of BRV. RESULTS: Data of 101 patients (mean age 42 years, range 18-81 years, 54 females,) were analyzed. The median number of antiepileptic drugs (AEDs) used prior to BRV was 10 (range 2-18)...
March 18, 2017: Seizure: the Journal of the British Epilepsy Association
https://www.readbyqxmd.com/read/28355045/schedules-of-controlled-substances-placement-of-brivaracetam-into-schedule-v-final-rule
#6
(no author information available yet)
This final rule adopts without change an interim final rule with request for comments published in the Federal Register on May 12, 2016. The Drug Enforcement Administration is placing the substance brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (also referred to as BRV; UCB-34714; Briviact) (including its salts) into schedule V of the Controlled Substances Act. This scheduling action is pursuant to the Controlled Substances Act, as revised by the Improving Regulatory Transparency for New Medical Therapies Act which was signed into law on November 25, 2015...
March 9, 2017: Federal Register
https://www.readbyqxmd.com/read/28335772/production-of-s-2-aminobutyric-acid-and-s-2-aminobutanol-in-saccharomyces-cerevisiae
#7
Nora Weber, Anaëlle Hatsch, Ludivine Labagnere, Harald Heider
BACKGROUND: Saccharomyces cerevisiae (baker's yeast) has great potential as a whole-cell biocatalyst for multistep synthesis of various organic molecules. To date, however, few examples exist in the literature of the successful biosynthetic production of chemical compounds, in yeast, that do not exist in nature. Considering that more than 30% of all drugs on the market are purely chemical compounds, often produced by harsh synthetic chemistry or with very low yields, novel and environmentally sound production routes are highly desirable...
March 23, 2017: Microbial Cell Factories
https://www.readbyqxmd.com/read/28331468/will-brivaracetam-help-my-patient-only-time-will-tell
#8
Jacqueline French
No abstract text is available yet for this article.
January 2017: Epilepsy Currents
https://www.readbyqxmd.com/read/28293101/new-developments-in-the-management-of-partial-onset-epilepsy-role-of-brivaracetam
#9
REVIEW
Giangennaro Coppola, Giulia Iapadre, Francesca Felicia Operto, Alberto Verrotti
Currently, a number of novel anticonvulsant drugs, the so-called third generation, are in various stages of development. Several of them are already available or in ongoing clinical trials. These new compounds should take advantage of new insights into the basic pathophysiology of epileptogenesis, drug metabolism and drug interactions. Many of them still need to be further evaluated mainly in real-world observational trials and registries. Among newer anticonvulsant drugs for partial-onset seizures (POSs), rufinamide, lacosamide, eslicarbazepine and perampanel are those new treatment options for which more substantial clinical evidence is currently available, both in adults and, to some extent, in children...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28280887/brivaracetam-population-pharmacokinetics-in-children-with-epilepsy-aged-1%C3%A2-month-to-16%C3%A2-years
#10
Rik Schoemaker, Janet R Wade, Armel Stockis
PURPOSE: The aims of the study were to develop a population pharmacokinetic model of orally administered brivaracetam in paediatric patients and to provide dosing suggestions. METHODS: Analysis included 600 brivaracetam plasma concentrations from a phase 2a study (NCT00422422; N01263) in 96 paediatric patients with epilepsy aged 1 month to 16 years, taking one to three concomitant antiepileptic drugs (AEDs). Pharmacokinetic analysis was performed using non-linear mixed effects modelling, and a stepwise covariate search was used to determine factors influencing brivaracetam clearance...
March 9, 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28279891/efficacy-and-tolerability-of-adjunctive-brivaracetam-in-patients-with-prior-antiepileptic-drug-exposure-a-post-hoc-study
#11
Ali A Asadi-Pooya, Michael R Sperling, Steve Chung, Pavel Klein, Anyzeila Diaz, Sami Elmoufti, Jimmy Schiemann, John Whitesides
Brivaracetam (BRV), a selective, high-affinity ligand for synaptic vesicle protein 2A, is a new antiepileptic drug (AED) for adjunctive treatment of focal (partial-onset) seizures in adults with epilepsy. This post-hoc analysis was conducted to explore the efficacy of adjunctive BRV in patients with prior levetiracetam (LEV) exposure and whether changes in efficacy were related to the similar mechanism of action of these two drugs. Data were pooled from three Phase III studies (NCT00490035; NCT00464269; NCT01261325) of adults with focal seizures taking 1-2 AEDs who received placebo or BRV 50-200mg/day without titration over a 12-week treatment period...
March 2017: Epilepsy Research
https://www.readbyqxmd.com/read/28236727/health-related-quality-of-life-in-double-blind-phase-iii-studies-of-brivaracetam-as-adjunctive-therapy-of-focal-seizures-a-pooled-post-hoc-analysis
#12
Christian Brandt, Simon Borghs, Sami Elmoufti, Knut Mueller, Rebecca Townsend, Christine de la Loge
PURPOSE: The effect of adjunctive brivaracetam on health-related quality of life (HRQoL) was assessed in a post-hoc analysis using pooled data from three randomized, double-blind, placebo-controlled Phase III studies in patients with refractory focal seizures (NCT00490035, NCT00464269, and NCT01261325). METHODS: The Patient-Weighted Quality of Life in Epilepsy Questionnaire (QOLIE-31-P) was completed at randomization, and weeks 4, 8 (in two of three studies), and 12 (end of the treatment period)...
February 22, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/28220535/interaction-of-approved-drugs-with-synaptic-vesicle-protein-2a
#13
Azeem Danish, Vigneshwaran Namasivayam, Anke C Schiedel, Christa E Müller
Levetiracetam (LEV) and its recently approved derivative brivaracetam are anti-epileptic drugs with a unique mechanism of action. The synaptic vesicle protein 2A (SV2A) was previously identified as their main target. In the current study, we tested a collection of 500 approved drugs for interaction with the human SV2A protein expressed in Chinese hamster ovary cells. Competition binding studies were performed using cell lysates with high SV2A expression and [(3) H]brivaracetam as a radioligand. A hit rate of 3% was obtained, defined as compounds that inhibited radioligand binding by more than 90% at a screening concentration of 20 μM...
February 21, 2017: Archiv der Pharmazie
https://www.readbyqxmd.com/read/28163554/brivaracetam-briviact-a-novel-adjunctive-therapy-for-partial-onset-seizures
#14
Farbod Khaleghi, Eric C Nemec
Brivaracetam (Briviact): a novel adjunctive therapy for partial-onset seizures.
February 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28111749/progress-report-on-new-antiepileptic-drugs-a-summary-of-the-thirteenth-eilat-conference-on-new-antiepileptic-drugs-and-devices-eilat-xiii
#15
REVIEW
Meir Bialer, Svein I Johannessen, René H Levy, Emilio Perucca, Torbjörn Tomson, H Steve White
The Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII) took place in Madrid, Spain, on June 26-29, 2016, and was attended by >200 delegates from 31 countries. The present Progress Report provides an update on experimental and clinical results for drugs presented at the Conference. Compounds for which summary data are presented include an AED approved in 2016 (brivaracetam), 12 drugs in phase I-III clinical development (adenosine, allopregnanolone, bumetanide, cannabidiol, cannabidivarin, 2-deoxy-d-glucose, everolimus, fenfluramine, huperzine A, minocycline, SAGE-217, and valnoctamide) and 6 compounds or classes of compounds for which only preclinical data are available (bumetanide derivatives, sec-butylpropylacetamide, FV-082, 1OP-2198, NAX 810-2, and SAGE-689)...
January 23, 2017: Epilepsia
https://www.readbyqxmd.com/read/28101765/tolerability-and-safety-of-commonly-used-antiepileptic-drugs-in-adolescents-and-adults-a-clinician-s-overview
#16
REVIEW
Martin J Brodie
This paper discusses the issues surrounding the tolerability and safety of the commonly used antiepileptic drugs (AEDs) in adolescents and adults. The content includes dose-related adverse effects, idiosyncratic reactions, behavioural and psychiatric comorbidities, chronic problems, enzyme induction and teratogenesis. Twenty-one AEDs are discussed in chronological order of their introduction into the UK, starting with phenobarbital and ending with brivaracetam. Wherever possible, advice is given on anticipating, recognising and managing these issues and thereby improving the lives of people with epilepsy, most of whom will need to take one or more of these agents for life...
February 2017: CNS Drugs
https://www.readbyqxmd.com/read/28012162/evidence-for-a-differential-interaction-of-brivaracetam-and-levetiracetam-with-the-synaptic-vesicle-2a-protein
#17
Martyn D Wood, Michel Gillard
OBJECTIVE: Brivaracetam (BRV) and levetiracetam (LEV) are effective antiepileptic drugs that bind selectively to the synaptic vesicle 2A (SV2A) protein. However, BRV differs from LEV in that it exhibits more potent and complete seizure suppression in animal models including in amygdala-kindled mice, where BRV afforded nearly complete seizure suppression. This raises the possibility that aside from potency differences, BRV and LEV may interact differently with the SV2A protein, which is not apparent in radioligand-binding competition studies...
February 2017: Epilepsia
https://www.readbyqxmd.com/read/28004320/sensitivity-and-responsiveness-of-the-eq-5d-3l-in-patients-with-uncontrolled-focal-seizures-an-analysis-of-phase-iii-trials-of-adjunctive-brivaracetam
#18
Clara Mukuria, Tracey Young, Anju Keetharuth, Simon Borghs, John Brazier
PURPOSE: Preference-based measures are required to measure the impact of interventions for cost-effectiveness analysis. This study assessed the psychometric performance of the EQ-5D-3L in adults with uncontrolled focal (partial-onset) seizures. METHODS: Data from three Phase III studies of an antiepileptic drug (adjunctive brivaracetam; n = 1095) were used. Analysis included correlations between EQ-5D-3L and Quality of Life in Epilepsy Inventory (QOLIE-31P) and seizure frequency...
March 2017: Quality of Life Research
https://www.readbyqxmd.com/read/27988967/time-to-onset-of-sustained-%C3%A2-50-responder-status-in-patients-with-focal-partial-onset-seizures-in-three-phase-iii-studies-of-adjunctive-brivaracetam-treatment
#19
Pavel Klein, Martin E Johnson, Jimmy Schiemann, John Whitesides
Time to onset of sustained ≥50% responder status (SRS) was assessed for the pooled patient population receiving brivaracetam (BRV) 50, 100, or 200 mg/day or placebo in three randomized phase III studies (NCT00464269, NCT00490035, and NCT01261325). Patients were aged ≥16 years with well-characterized focal (partial-onset) seizures (FS) uncontrolled by 1-2 concomitant antiepileptic drugs. After an 8-week baseline period, patients received study drug without up-titration for a 12-week (84-day) treatment period...
December 18, 2016: Epilepsia
https://www.readbyqxmd.com/read/27970520/cost-effectiveness-of-brivaracetam-versus-other-antiepileptic-drugs-used-as-adjunctive-treatment-for-focal-seizures-in-the-uk-a-discrete-event-simulation-model
#20
M Charokopou, J Sander, R Saha, S Beard, R Kidd, E Coward, J Plumb
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
110670
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"